首頁 > 市場調查報告書 > 製藥

孤兒藥

市場調查報告書

商品編碼

1467655

2024-2032 年按藥物類型、疾病類型、階段、最暢銷藥物、配銷通路和地區分類的孤兒藥市場報告

Orphan Drugs Market Report by Drug Type, Disease Type, Phase, Top Selling Drugs, Distribution Channel, and Region 2024-2032

出版日期: 2024年04月08日 | 出版商:

IMARC | 英文 135 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄圖表

2023年全球孤兒藥市場規模達2,148億IMARC Group。

孤兒藥是指用於診斷、預防和治療罕見疾病的藥品。這些藥物是為了滿足特定的公共衛生要求而生產的，通常市場有限，因為它們是為一小部分患者生產的。它們可有效對抗多種腫瘤、代謝、血液、免疫、感染和神經疾病。淋巴瘤、白血病、囊性纖維化、神經膠質瘤、胰臟癌、卵巢癌、多發性骨髓瘤和腎細胞癌等醫療疾病通常是危及生命的、慢性的、進行性的、退化性的和致殘的，需要有效的特定治療方案。

孤兒藥市場趨勢：

癌症和其他罕見遺傳性疾病盛行率的增加是推動市場成長的關鍵因素之一。製藥商正在開發創新的孤兒藥，為患者提供個人化治療。大眾對孤兒藥益處的認知不斷提高，也推動了市場的發展。新藥品製造商的出現以及政府抑制傳染病傳播的有利政策的實施也促進了市場的成長。此外，各種產品創新，例如生物孤兒藥的開發，也是其他成長誘導因素。這些藥物可以治療癌症等疾病，並逆轉對幹細胞造成的傷害，這極大地促進了它們的整體需求。其他因素，包括醫療保健基礎設施的改善以及廣泛的研發（R&D）活動，預計將進一步推動市場發展。

本報告回答的關鍵問題

2023年全球孤兒藥市場規模有多大？
2024-2032年全球孤兒藥市場的預期成長率是多少？
推動全球孤兒藥市場的關鍵因素是什麼？
COVID-19 對全球孤兒藥市場有何影響？
全球孤兒藥市場按藥物類型分類是怎樣的？
根據疾病類型，全球孤兒藥市場的細分如何？
基於最暢銷藥物的全球孤兒藥市場的分類是怎樣的？
全球孤兒藥市場基於配銷通路的詳細情形如何？
全球孤兒藥市場的重點區域有哪些？
全球孤兒藥市場的主要參與者/公司有哪些？

來那度胺
- 市場走向
- 市場預測
利妥昔單抗
- 市場走向
- 市場預測
科帕松
- 市場走向
- 市場預測
奧狄沃
- 市場走向
- 市場預測
可瑞達
- 市場走向
- 市場預測
伊布維察
- 市場走向
- 市場預測
埃沃內克斯
- 市場走向
- 市場預測
森西帕
- 市場走向
- 市場預測
依庫珠單抗
- 市場走向
- 市場預測
其他
- 市場走向
- 市場預測

第 10 章：市場區隔：按配銷通路

醫院藥房
- 市場走向
- 市場預測
零售藥局
- 市場走向
- 市場預測
網路商店
- 市場走向
- 市場預測
其他
- 市場走向
- 市場預測

第 11 章：市場區隔：按地區

北美洲
- 美國
  - 市場走向
  - 市場預測
- 加拿大
  - 市場走向
  - 市場預測
亞太地區
- 中國
  - 市場走向
  - 市場預測
- 日本
  - 市場走向
  - 市場預測
- 印度
  - 市場走向
  - 市場預測
- 韓國
  - 市場走向
  - 市場預測
- 澳洲
  - 市場走向
  - 市場預測
- 印尼
  - 市場走向
  - 市場預測
- 其他
  - 市場走向
  - 市場預測
歐洲
- 德國
  - 市場走向
  - 市場預測
- 法國
  - 市場走向
  - 市場預測
- 英國
  - 市場走向
  - 市場預測
- 義大利
  - 市場走向
  - 市場預測
- 西班牙
  - 市場走向
  - 市場預測
- 俄羅斯
  - 市場走向
  - 市場預測
- 其他
  - 市場走向
  - 市場預測
拉丁美洲
- 巴西
  - 市場走向
  - 市場預測
- 墨西哥
  - 市場走向
  - 市場預測
- 其他
  - 市場走向
  - 市場預測
中東和非洲
- 市場走向
- 市場細分：按國家/地區
- 市場預測

第 12 章：SWOT 分析

概述
優勢
弱點
機會
威脅

第 13 章：價值鏈分析

第 14 章：波特五力分析

概述
買家的議價能力
供應商的議價能力
競爭程度
新進入者的威脅
替代品的威脅

第 15 章：價格分析

第16章：競爭格局

市場結構
關鍵參與者
關鍵參與者簡介
- AbbVie Inc.
- Alexion Pharmaceuticals Inc.
- Amgen Inc.
- Biogen Inc.
- Bristol Myers Squibb Company
- F. Hoffmann-La Roche AG (Roche Holding AG)
- Jazz Pharmaceuticals Plc
- Johnson & Johnson
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi SA
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Ltd

簡介目錄圖表

Product Code: SR112024A2382

The global orphan drugs market size reached US$ 214.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 541.3 Billion by 2032, exhibiting a growth rate (CAGR) of 10.5% during 2024-2032.

Orphan drugs refer to pharmaceutical products used for the diagnosis, prevention and treatment of rare medical disorders. These drugs are manufactured to meet a specific public health requirement and usually have a limited market as they are produced for a small group of patients. They are effective against numerous oncological, metabolic, hematologic, immunologic, infectious and neurological diseases. Medical ailments, such as lymphoma, leukemia, cystic fibrosis, glioma, pancreatic cancer, ovarian cancer, multiple myeloma and renal cell carcinoma, are often life-threatening, chronic, progressive, degenerative and disabling and require specific treatment alternatives that are effective for their particular symptoms.

Orphan Drugs Market Trends:

The increasing prevalence of cancer and other rare genetic disorders is one of the key factors driving the growth of the market. Pharmaceutical manufacturers are developing innovative orphan drugs to provide personalized therapy to patients. The market is also being driven by increasing awareness among the masses regarding the benefits of orphan drugs. The emergence of new pharmaceutical drug manufacturers and the implementation of favorable government policies to inhibit the spread of contagious diseases are also contributing to the market growth. Additionally, various product innovations, such as the development of biological orphan drugs, are acting as other growth-inducing factors. These drugs can treat diseases, such as cancer, and reverse the damage caused to the stem cells, which is facilitating their overall demand significantly. Other factors, including improvements in the healthcare infrastructure, along with extensive research and development (R&D) activities, are expected to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global orphan drugs market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on drug type, disease type, phase, top selling drugs and distribution channel.

Breakup by Drug Type:

Biological

Non-Biological

Breakup by Disease Type:

Oncology

Hematology

Neurology

Cardiovascular

Others

Breakup by Phase:

Phase I

Phase II

Phase III

Phase IV

Breakup by Top Selling Drugs:

Revlimid

Rituxan

Copaxone

Opdivo

Keytruda

Imbruvica

Avonex

Sensipar

Soliris

Others

Breakup by Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Stores

Others

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being AbbVie Inc., Alexion Pharmaceuticals Inc., Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG (Roche Holding AG), Jazz Pharmaceuticals Plc, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report

1. What was the size of the global orphan drugs market in 2023?
2. What is the expected growth rate of the global orphan drugs market during 2024-2032?
3. What are the key factors driving the global orphan drugs market?
4. What has been the impact of COVID-19 on the global orphan drugs market?
5. What is the breakup of the global orphan drugs market based on the drug type?
6. What is the breakup of the global orphan drugs market based on the disease type?
7. What is the breakup of the global orphan drugs market based on top selling drugs?
8. What is the breakup of the global orphan drugs market based on the distribution channel?
9. What are the key regions in the global orphan drugs market?
10. Who are the key players/companies in the global orphan drugs market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Orphan Drugs Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Drug Type

6.1 Biological
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Non-Biological
- 6.2.1 Market Trends
- 6.2.2 Market Forecast

7 Market Breakup by Disease Type

7.1 Oncology
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Hematology
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
7.3 Neurology
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
7.4 Cardiovascular
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
7.5 Others
- 7.5.1 Market Trends
- 7.5.2 Market Forecast

8 Market Breakup by Phase

8.1 Phase I
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Phase II
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
8.3 Phase III
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
8.4 Phase IV
- 8.4.1 Market Trends
- 8.4.2 Market Forecast

9 Market Breakup by Top Selling Drugs

9.1 Revlimid
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
9.2 Rituxan
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
9.3 Copaxone
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
9.4 Opdivo
- 9.4.1 Market Trends
- 9.4.2 Market Forecast
9.5 Keytruda
- 9.5.1 Market Trends
- 9.5.2 Market Forecast
9.6 Imbruvica
- 9.6.1 Market Trends
- 9.6.2 Market Forecast
9.7 Avonex
- 9.7.1 Market Trends
- 9.7.2 Market Forecast
9.8 Sensipar
- 9.8.1 Market Trends
- 9.8.2 Market Forecast
9.9 Soliris
- 9.9.1 Market Trends
- 9.9.2 Market Forecast
9.10 Others
- 9.10.1 Market Trends
- 9.10.2 Market Forecast

10 Market Breakup by Distribution Channel

10.1 Hospital Pharmacies
- 10.1.1 Market Trends
- 10.1.2 Market Forecast
10.2 Retail Pharmacies
- 10.2.1 Market Trends
- 10.2.2 Market Forecast
10.3 Online Stores
- 10.3.1 Market Trends
- 10.3.2 Market Forecast
10.4 Others
- 10.4.1 Market Trends
- 10.4.2 Market Forecast

11 Market Breakup by Region

11.1 North America
- 11.1.1 United States
  - 11.1.1.1 Market Trends
  - 11.1.1.2 Market Forecast
- 11.1.2 Canada
  - 11.1.2.1 Market Trends
  - 11.1.2.2 Market Forecast
11.2 Asia Pacific
- 11.2.1 China
  - 11.2.1.1 Market Trends
  - 11.2.1.2 Market Forecast
- 11.2.2 Japan
  - 11.2.2.1 Market Trends
  - 11.2.2.2 Market Forecast
- 11.2.3 India
  - 11.2.3.1 Market Trends
  - 11.2.3.2 Market Forecast
- 11.2.4 South Korea
  - 11.2.4.1 Market Trends
  - 11.2.4.2 Market Forecast
- 11.2.5 Australia
  - 11.2.5.1 Market Trends
  - 11.2.5.2 Market Forecast
- 11.2.6 Indonesia
  - 11.2.6.1 Market Trends
  - 11.2.6.2 Market Forecast
- 11.2.7 Others
  - 11.2.7.1 Market Trends
  - 11.2.7.2 Market Forecast
11.3 Europe
- 11.3.1 Germany
  - 11.3.1.1 Market Trends
  - 11.3.1.2 Market Forecast
- 11.3.2 France
  - 11.3.2.1 Market Trends
  - 11.3.2.2 Market Forecast
- 11.3.3 United Kingdom
  - 11.3.3.1 Market Trends
  - 11.3.3.2 Market Forecast
- 11.3.4 Italy
  - 11.3.4.1 Market Trends
  - 11.3.4.2 Market Forecast
- 11.3.5 Spain
  - 11.3.5.1 Market Trends
  - 11.3.5.2 Market Forecast
- 11.3.6 Russia
  - 11.3.6.1 Market Trends
  - 11.3.6.2 Market Forecast
- 11.3.7 Others
  - 11.3.7.1 Market Trends
  - 11.3.7.2 Market Forecast
11.4 Latin America
- 11.4.1 Brazil
  - 11.4.1.1 Market Trends
  - 11.4.1.2 Market Forecast
- 11.4.2 Mexico
  - 11.4.2.1 Market Trends
  - 11.4.2.2 Market Forecast
- 11.4.3 Others
  - 11.4.3.1 Market Trends
  - 11.4.3.2 Market Forecast
11.5 Middle East and Africa
- 11.5.1 Market Trends
- 11.5.2 Market Breakup by Country
- 11.5.3 Market Forecast

12 SWOT Analysis

12.1 Overview
12.2 Strengths
12.3 Weaknesses
12.4 Opportunities
12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

14.1 Overview
14.2 Bargaining Power of Buyers
14.3 Bargaining Power of Suppliers
14.4 Degree of Competition
14.5 Threat of New Entrants
14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

16.1 Market Structure
16.2 Key Players
16.3 Profiles of Key Players
- 16.3.1 AbbVie Inc.
  - 16.3.1.1 Company Overview
  - 16.3.1.2 Product Portfolio
  - 16.3.1.3 Financials
  - 16.3.1.4 SWOT Analysis
- 16.3.2 Alexion Pharmaceuticals Inc.
  - 16.3.2.1 Company Overview
  - 16.3.2.2 Product Portfolio
  - 16.3.2.3 Financials
  - 16.3.2.4 SWOT Analysis
- 16.3.3 Amgen Inc.
  - 16.3.3.1 Company Overview
  - 16.3.3.2 Product Portfolio
  - 16.3.3.3 Financials
  - 16.3.3.4 SWOT Analysis
- 16.3.4 Biogen Inc.
  - 16.3.4.1 Company Overview
  - 16.3.4.2 Product Portfolio
  - 16.3.4.3 Financials
  - 16.3.4.4 SWOT Analysis
- 16.3.5 Bristol Myers Squibb Company
  - 16.3.5.1 Company Overview
  - 16.3.5.2 Product Portfolio
  - 16.3.5.3 Financials
  - 16.3.5.4 SWOT Analysis
- 16.3.6 F. Hoffmann-La Roche AG (Roche Holding AG)
  - 16.3.6.1 Company Overview
  - 16.3.6.2 Product Portfolio
  - 16.3.6.3 SWOT Analysis
- 16.3.7 Jazz Pharmaceuticals Plc
  - 16.3.7.1 Company Overview
  - 16.3.7.2 Product Portfolio
  - 16.3.7.3 Financials
  - 16.3.7.4 SWOT Analysis
- 16.3.8 Johnson & Johnson
  - 16.3.8.1 Company Overview
  - 16.3.8.2 Product Portfolio
  - 16.3.8.3 Financials
  - 16.3.8.4 SWOT Analysis
- 16.3.9 Merck & Co. Inc.
  - 16.3.9.1 Company Overview
  - 16.3.9.2 Product Portfolio
  - 16.3.9.3 Financials
  - 16.3.9.4 SWOT Analysis
- 16.3.10 Novartis AG
  - 16.3.10.1 Company Overview
  - 16.3.10.2 Product Portfolio
  - 16.3.10.3 Financials
  - 16.3.10.4 SWOT Analysis
- 16.3.11 Pfizer Inc.
  - 16.3.11.1 Company Overview
  - 16.3.11.2 Product Portfolio
  - 16.3.11.3 Financials
  - 16.3.11.4 SWOT Analysis
- 16.3.12 Sanofi S.A.
  - 16.3.12.1 Company Overview
  - 16.3.12.2 Product Portfolio
  - 16.3.12.3 Financials
  - 16.3.12.4 SWOT Analysis
- 16.3.13 Takeda Pharmaceutical Company Limited
  - 16.3.13.1 Company Overview
  - 16.3.13.2 Product Portfolio
  - 16.3.13.3 Financials
  - 16.3.13.4 SWOT Analysis
- 16.3.14 Teva Pharmaceutical Industries Ltd
  - 16.3.14.1 Company Overview
  - 16.3.14.2 Product Portfolio
  - 16.3.14.3 Financials
  - 16.3.14.4 SWOT Analysis

簡介目錄圖表

List of Figures

Figure 1: Global: Orphan Drugs Market: Major Drivers and Challenges
Figure 2: Global: Orphan Drugs Market: Sales Value (in Billion US$), 2018-2023
Figure 3: Global: Orphan Drugs Market: Breakup by Drug Type (in %), 2023
Figure 4: Global: Orphan Drugs Market: Breakup by Disease Type (in %), 2023
Figure 5: Global: Orphan Drugs Market: Breakup by Phase (in %), 2023
Figure 6: Global: Orphan Drugs Market: Breakup by Top Selling Drugs (in %), 2023
Figure 7: Global: Orphan Drugs Market: Breakup by Distribution Channel (in %), 2023
Figure 8: Global: Orphan Drugs Market: Breakup by Region (in %), 2023
Figure 9: Global: Orphan Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
Figure 10: Global: Orphan Drugs (Biological) Market: Sales Value (in Million US$), 2018 & 2023
Figure 11: Global: Orphan Drugs (Biological) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 12: Global: Orphan Drugs (Non-Biological) Market: Sales Value (in Million US$), 2018 & 2023
Figure 13: Global: Orphan Drugs (Non-Biological) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 14: Global: Orphan Drugs (Oncology) Market: Sales Value (in Million US$), 2018 & 2023
Figure 15: Global: Orphan Drugs (Oncology) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 16: Global: Orphan Drugs (Hematology) Market: Sales Value (in Million US$), 2018 & 2023
Figure 17: Global: Orphan Drugs (Hematology) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 18: Global: Orphan Drugs (Neurology) Market: Sales Value (in Million US$), 2018 & 2023
Figure 19: Global: Orphan Drugs (Neurology) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 20: Global: Orphan Drugs (Cardiovascular) Market: Sales Value (in Million US$), 2018 & 2023
Figure 21: Global: Orphan Drugs (Cardiovascular) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 22: Global: Orphan Drugs (Other Disease Types) Market: Sales Value (in Million US$), 2018 & 2023
Figure 23: Global: Orphan Drugs (Other Disease Types) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 24: Global: Orphan Drugs (Phase I) Market: Sales Value (in Million US$), 2018 & 2023
Figure 25: Global: Orphan Drugs (Phase I) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 26: Global: Orphan Drugs (Phase II) Market: Sales Value (in Million US$), 2018 & 2023
Figure 27: Global: Orphan Drugs (Phase II) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 28: Global: Orphan Drugs (Phase III) Market: Sales Value (in Million US$), 2018 & 2023
Figure 29: Global: Orphan Drugs (Phase III) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 30: Global: Orphan Drugs (Phase IV) Market: Sales Value (in Million US$), 2018 & 2023
Figure 31: Global: Orphan Drugs (Phase IV) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 32: Global: Orphan Drugs (Revlimid) Market: Sales Value (in Million US$), 2018 & 2023
Figure 33: Global: Orphan Drugs (Revlimid) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 34: Global: Orphan Drugs (Rituxan) Market: Sales Value (in Million US$), 2018 & 2023
Figure 35: Global: Orphan Drugs (Rituxan) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 36: Global: Orphan Drugs (Copaxone) Market: Sales Value (in Million US$), 2018 & 2023
Figure 37: Global: Orphan Drugs (Copaxone) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 38: Global: Orphan Drugs (Opdivo) Market: Sales Value (in Million US$), 2018 & 2023
Figure 39: Global: Orphan Drugs (Opdivo) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 40: Global: Orphan Drugs (Keytruda) Market: Sales Value (in Million US$), 2018 & 2023
Figure 41: Global: Orphan Drugs (Keytruda) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 42: Global: Orphan Drugs (Imbruvica) Market: Sales Value (in Million US$), 2018 & 2023
Figure 43: Global: Orphan Drugs (Imbruvica) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 44: Global: Orphan Drugs (Avonex) Market: Sales Value (in Million US$), 2018 & 2023
Figure 45: Global: Orphan Drugs (Avonex) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 46: Global: Orphan Drugs (Sensipar) Market: Sales Value (in Million US$), 2018 & 2023
Figure 47: Global: Orphan Drugs (Sensipar) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 48: Global: Orphan Drugs (Soliris) Market: Sales Value (in Million US$), 2018 & 2023
Figure 49: Global: Orphan Drugs (Soliris) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 50: Global: Orphan Drugs (Other Drugs) Market: Sales Value (in Million US$), 2018 & 2023
Figure 51: Global: Orphan Drugs (Other Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 52: Global: Orphan Drugs (Hospital Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
Figure 53: Global: Orphan Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 54: Global: Orphan Drugs (Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
Figure 55: Global: Orphan Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 56: Global: Orphan Drugs (Online Stores) Market: Sales Value (in Million US$), 2018 & 2023
Figure 57: Global: Orphan Drugs (Online Stores) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 58: Global: Orphan Drugs (Other Distribution Channels) Market: Sales Value (in Million US$), 2018 & 2023
Figure 59: Global: Orphan Drugs (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 60: North America: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 61: North America: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 62: United States: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 63: United States: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 64: Canada: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 65: Canada: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 66: Asia Pacific: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 67: Asia Pacific: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 68: China: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 69: China: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 70: Japan: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 71: Japan: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 72: India: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 73: India: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 74: South Korea: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 75: South Korea: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 76: Australia: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 77: Australia: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 78: Indonesia: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 79: Indonesia: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 80: Others: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 81: Others: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 82: Europe: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 83: Europe: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 84: Germany: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 85: Germany: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 86: France: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 87: France: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 88: United Kingdom: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 89: United Kingdom: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 90: Italy: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 91: Italy: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 92: Spain: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 93: Spain: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 94: Russia: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 95: Russia: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 96: Others: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 97: Others: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 98: Latin America: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 99: Latin America: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 100: Brazil: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 101: Brazil: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 102: Mexico: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 103: Mexico: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 104: Others: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 105: Others: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 106: Middle East and Africa: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 107: Middle East and Africa: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 108: Global: Orphan Drugs Industry: SWOT Analysis
Figure 109: Global: Orphan Drugs Industry: Value Chain Analysis
Figure 110: Global: Orphan Drugs Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Orphan Drugs Market: Key Industry Highlights, 2023 and 2032
Table 2: Global: Orphan Drugs Market Forecast: Breakup by Drug Type (in Million US$), 2024-2032
Table 3: Global: Orphan Drugs Market Forecast: Breakup by Disease Type (in Million US$), 2024-2032
Table 4: Global: Orphan Drugs Market Forecast: Breakup by Phase (in Million US$), 2024-2032
Table 5: Global: Orphan Drugs Market Forecast: Breakup by Top Selling Drugs (in Million US$), 2024-2032
Table 6: Global: Orphan Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
Table 7: Global: Orphan Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
Table 8: Global: Orphan Drugs Market Structure
Table 9: Global: Orphan Drugs Market: Key Players

02-2729-4219

+886-2-2729-4219